Short Interest in Pharvaris (NASDAQ:PHVS) Expands By 39.5%

Pharvaris (NASDAQ:PHVS) saw a significant growth in short interest in August. As of August 31st, there was short interest totalling 181,400 shares, a growth of 39.5% from the August 15th total of 130,000 shares. Based on an average trading volume of 78,200 shares, the short-interest ratio is presently 2.3 days. Approximately 1.0% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Oppenheimer increased their price objective on shares of Pharvaris from $38.00 to $42.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.60.

Pharvaris Price Performance

Shares of PHVS stock traded down $0.32 on Monday, hitting $20.60. The stock had a trading volume of 136,277 shares, compared to its average volume of 85,952. The stock’s 50 day moving average is $18.14 and its 200-day moving average is $20.00. Pharvaris has a 52-week low of $15.00 and a 52-week high of $33.00.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 14th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.02). Equities research analysts anticipate that Pharvaris will post -2.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Blackstone Inc. purchased a new position in shares of Pharvaris in the fourth quarter valued at $2,805,000. Sofinnova Investments Inc. boosted its stake in shares of Pharvaris by 2.9% in the second quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock valued at $11,309,000 after purchasing an additional 16,862 shares during the period. Commodore Capital LP purchased a new position in shares of Pharvaris in the fourth quarter valued at $22,440,000. Deerfield Management Company L.P. Series C boosted its stake in Pharvaris by 31.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock valued at $26,269,000 after acquiring an additional 335,687 shares during the last quarter. Finally, Novo Holdings A S boosted its stake in Pharvaris by 47.7% during the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock valued at $32,430,000 after acquiring an additional 556,970 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.